An interventional study of aCPR algorithm and ERC ALS 2025 in Cardiac Arrest (CA), sponsored by Johannes Kepler University of Linz. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Johannes Kepler University of Linz · Not applicable, Interventional, and Treatment
The goal of this controlled single centre RCT is to compare frequency rates concerning return of spontaneous circulation (ROSC) in prehospital cardiac arrest. Two different algorithms (control-and interventiongroup) of advanced cardiac life support will be used to treat patients. In patients over 18 years suffering from cardiac arrest. The main question aims to answer if the frequency of ROSC differs between the groups receiving either the new Advanced Life Support (ALS) algorithm, or standard treatment.
Researchers will compare the new algorithm to the standard care algorithm to see if there is a difference .
Participants will be randomized to treatment on scene. The controlgroup will receive ALS standard treatment as performed in local protocols.
The intervention group will receive a modified treatment including:
926 studies on the registry are indexed under Heart Arrest; 226 are open to participants now.
This study's planned enrollment of 216 is above the median of 100 across 518 interventional studies indexed under Heart Arrest.
Browse Heart Arrest studies →Johannes Kepler University of Linz is the lead sponsor of 33 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: ERC ALS 2025
* thorax compression via mechanical device (LUCAS 3) * head up cpr * use of an ITD module * arterial line placement * continuous epinephrin infusion via infusion pump * double sequence defibrillation
Procedure: aCPR algorithm
* thorax compression via mechanical device (LUCAS 3) * head up cpr * use of an ITD module * arterial line placement * continuous epinephrin infusion via infusion pump * double sequence defibrillation
Placement of an IV line, placement of a supraglottic airway device or endotracheal intubation. Optional use of an intraosseus acces
ROSC
frequency of ROSC in the study cohort
Time frame: one minute
Time to ROSC
comparison between the groups if ROSC can be achieved faster in one group
Time frame: Periprocedural: from enrollement to ROSC or Termination of Resuscitation (TOR)
CO2
Measurement of CO2 differences between study arms
Time frame: Periprocedural: from enrollement to ROSC orTOR
descriptive data
analyzing vital parameters measured
Time frame: Periprocedural: during study intervention
Plan to share: No — Deidentified participant data utilized in this study can be made available upon reasonable request to the corresponding author. Access to the data will be subject to approval by institutional and ethical considerations.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2029, 36 months after the start.
Of 204 non-industry interventional studies with no phase under Heart Arrest, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's planned 36 months is above that.
Counting every sponsor, half of 218 studies reached it within 28 months; a quarter within 10 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johannes Kepler University of Linz